STOCK TITAN

[Form 4] Streamline Health Solutions, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Matthew Etheridge, a director of Streamline Health Solutions, reported dispositions tied to a merger that took effect on 08/12/2025. Under the Merger Agreement dated May 29, 2025, the company became a wholly owned subsidiary of Mist Holding Co., and each outstanding share of Streamline common stock was canceled and converted into the right to receive $5.34 in cash per share. The filing notes numbers were adjusted for a 1-for-15 reverse stock split effected on October 4, 2024.

The Form 4 shows Mr. Etheridge disposed of 30,876 common shares resulting in 0 common shares beneficially owned following the transaction. It also reports 61,403 underlying shares from Company warrants (exercise price listed as $5.85) that were canceled; warrants with exercise prices equal to or above the merger consideration were canceled for no consideration.

Matthew Etheridge, direttore di Streamline Health Solutions, ha segnalato disposizioni legate a una fusione entrata in vigore il 08/12/2025. In base all'Accordo di Fusione datato 29 maggio 2025, la società è diventata una controllata interamente posseduta da Mist Holding Co. e ogni azione ordinaria Streamline in circolazione è stata annullata e convertita nel diritto a ricevere $5.34 in contanti per azione. La comunicazione specifica che i numeri sono stati rettificati per un reverse stock split 1-for-15 effettuato il 4 ottobre 2024.

Il Modulo 4 indica che il Sig. Etheridge ha ceduto 30,876 azioni ordinarie, risultando con 0 azioni ordinarie di proprietà effettiva dopo la transazione. Riporta inoltre che 61,403 azioni sottostanti provenienti da warrant della Società (prezzo di esercizio indicato $5.85) sono state annullate; i warrant con prezzi di esercizio pari o superiori alla controparte della fusione sono stati annullati senza alcun corrispettivo.

Matthew Etheridge, director de Streamline Health Solutions, informó disposiciones vinculadas a una fusión que entró en vigor el 08/12/2025. Según el Acuerdo de Fusión fechado el 29 de mayo de 2025, la compañía pasó a ser una filial de propiedad total de Mist Holding Co., y cada acción ordinaria en circulación de Streamline fue cancelada y convertida en el derecho a recibir $5.34 en efectivo por acción. La presentación señala que las cifras se ajustaron por una consolidación de acciones 1-for-15 efectuada el 4 de octubre de 2024.

El Formulario 4 muestra que el Sr. Etheridge dispuso de 30,876 acciones ordinarias, quedando con 0 acciones ordinarias de propiedad beneficiaria tras la transacción. También informa que 61,403 acciones subyacentes procedentes de warrants de la Compañía (precio de ejercicio indicado $5.85) fueron canceladas; los warrants con precios de ejercicio iguales o superiores a la contraprestación de la fusión fueron cancelados sin compensación.

Matthew Etheridge는 Streamline Health Solutions의 이사로서 08/12/2025에 발효된 합병과 관련된 처분을 보고했습니다. 2025년 5월 29일자 합병계약에 따라 회사는 Mist Holding Co.의 전액 출자 자회사가 되었고, 모든 발행된 Streamline 보통주는 취소되어 주당 $5.34의 현금을 받을 권리로 전환되었습니다. 제출 서류에는 2024년 10월 4일 시행된 1-for-15 역병합을 반영해 수치가 조정되었다고 기재되어 있습니다.

Form 4에는 Etheridge 씨가 30,876주의 보통주를 처분하여 거래 후 보유 유익소유 주식 수가 0가 되었다고 나와 있습니다. 또한 행사 가격이 $5.85로 기재된 회사 워런트에서 발생한 61,403개의 기초 주식이 취소되었음을 보고하며, 합병 보상과 같거나 높은 행사 가격을 가진 워런트는 대가 없이 취소되었습니다.

Matthew Etheridge, administrateur de Streamline Health Solutions, a déclaré des cessions liées à une fusion entrée en vigueur le 08/12/2025. En vertu de l'accord de fusion daté du 29 mai 2025, la société est devenue une filiale entièrement détenue par Mist Holding Co., et chaque action ordinaire en circulation de Streamline a été annulée et convertie en droit de recevoir $5.34 en espèces par action. Le dépôt précise que les chiffres ont été ajustés pour tenir compte d'un fractionnement inversé d'actions 1-for-15 effectué le 4 octobre 2024.

Le Formulaire 4 indique que M. Etheridge a cédé 30,876 actions ordinaires, se retrouvant avec 0 action ordinaire détenue à titre bénéficiaire après la transaction. Il signale également que 61,403 actions sous-jacentes issues de warrants de la société (prix d'exercice indiqué $5.85) ont été annulées ; les warrants dont le prix d'exercice est égal ou supérieur à la contrepartie de la fusion ont été annulés sans contrepartie.

Matthew Etheridge, Direktor von Streamline Health Solutions, meldete Veräußerungen im Zusammenhang mit einer Fusion, die am 08/12/2025 wirksam wurde. Gemäß dem am 29. Mai 2025 abgeschlossenen Fusionsvertrag wurde das Unternehmen eine hundertprozentige Tochtergesellschaft von Mist Holding Co., und jede ausstehende Streamline-Stammaktie wurde annulliert und in das Recht umgewandelt, pro Aktie $5.34 in bar zu erhalten. Die Einreichung weist darauf hin, dass die Zahlen an einen 1-for-15 Reverse Stock Split angepasst wurden, der am 4. Oktober 2024 durchgeführt wurde.

Das Form 4 zeigt, dass Herr Etheridge 30,876 Stammaktien veräußerte und nach der Transaktion 0 Stammaktien vorteilhaft besitzt. Es berichtet außerdem über 61,403 zugrunde liegende Aktien aus Unternehmens-Warrants (Ausübungspreis angegeben mit $5.85), die annulliert wurden; Warrants mit Ausübungspreisen, die gleich oder höher als die Fusionsgegenleistung waren, wurden ohne Gegenleistung annulliert.

Positive
  • Merger consideration of $5.34 per common share provides a cash exit for shareholders
  • Transaction effective date (08/12/2025) and reporting show the merger and conversion were completed
Negative
  • 61,403 warrant-based shares were canceled; warrants with a $5.85 exercise price were canceled for no consideration
  • Reporting person’s beneficial ownership of common stock and warrants is shown as 0 following the transaction, indicating loss of ongoing equity stake

Insights

TL;DR: Form 4 documents a merger closing that converted common shares to $5.34 cash and canceled certain warrants.

The filing confirms the Merger Agreement became effective on 08/12/2025, converting each outstanding share into $5.34 cash and extinguishing public equity. The reported figures — 30,876 common shares disposed and 61,403 warrant-related underlying shares canceled — reflect the post-1-for-15 reverse-split adjusted counts. For holders, common shares received cash consideration while warrants with an exercise price at or above $5.34 were canceled for no consideration, per the agreement. This is a material corporate action that finalizes consideration to holders and ends their equity exposure.

TL;DR: Insider Form 4 confirms corporate control change and extinguishment of public equity and certain derivative claims.

The Form 4 provides clear documentation that Streamline Health became a wholly owned subsidiary of the acquirer at the Effective Time, with outstanding common shares canceled for $5.34 per share and certain warrants canceled without payment where the exercise price met or exceeded the merger consideration. The reporting director's beneficial ownership is reduced to zero for both common stock and warrants, evidencing completion of the transaction and transfer of economic rights to the merger consideration. This filing is a definitive, material disclosure about corporate control and investor pay-out mechanics.

Matthew Etheridge, direttore di Streamline Health Solutions, ha segnalato disposizioni legate a una fusione entrata in vigore il 08/12/2025. In base all'Accordo di Fusione datato 29 maggio 2025, la società è diventata una controllata interamente posseduta da Mist Holding Co. e ogni azione ordinaria Streamline in circolazione è stata annullata e convertita nel diritto a ricevere $5.34 in contanti per azione. La comunicazione specifica che i numeri sono stati rettificati per un reverse stock split 1-for-15 effettuato il 4 ottobre 2024.

Il Modulo 4 indica che il Sig. Etheridge ha ceduto 30,876 azioni ordinarie, risultando con 0 azioni ordinarie di proprietà effettiva dopo la transazione. Riporta inoltre che 61,403 azioni sottostanti provenienti da warrant della Società (prezzo di esercizio indicato $5.85) sono state annullate; i warrant con prezzi di esercizio pari o superiori alla controparte della fusione sono stati annullati senza alcun corrispettivo.

Matthew Etheridge, director de Streamline Health Solutions, informó disposiciones vinculadas a una fusión que entró en vigor el 08/12/2025. Según el Acuerdo de Fusión fechado el 29 de mayo de 2025, la compañía pasó a ser una filial de propiedad total de Mist Holding Co., y cada acción ordinaria en circulación de Streamline fue cancelada y convertida en el derecho a recibir $5.34 en efectivo por acción. La presentación señala que las cifras se ajustaron por una consolidación de acciones 1-for-15 efectuada el 4 de octubre de 2024.

El Formulario 4 muestra que el Sr. Etheridge dispuso de 30,876 acciones ordinarias, quedando con 0 acciones ordinarias de propiedad beneficiaria tras la transacción. También informa que 61,403 acciones subyacentes procedentes de warrants de la Compañía (precio de ejercicio indicado $5.85) fueron canceladas; los warrants con precios de ejercicio iguales o superiores a la contraprestación de la fusión fueron cancelados sin compensación.

Matthew Etheridge는 Streamline Health Solutions의 이사로서 08/12/2025에 발효된 합병과 관련된 처분을 보고했습니다. 2025년 5월 29일자 합병계약에 따라 회사는 Mist Holding Co.의 전액 출자 자회사가 되었고, 모든 발행된 Streamline 보통주는 취소되어 주당 $5.34의 현금을 받을 권리로 전환되었습니다. 제출 서류에는 2024년 10월 4일 시행된 1-for-15 역병합을 반영해 수치가 조정되었다고 기재되어 있습니다.

Form 4에는 Etheridge 씨가 30,876주의 보통주를 처분하여 거래 후 보유 유익소유 주식 수가 0가 되었다고 나와 있습니다. 또한 행사 가격이 $5.85로 기재된 회사 워런트에서 발생한 61,403개의 기초 주식이 취소되었음을 보고하며, 합병 보상과 같거나 높은 행사 가격을 가진 워런트는 대가 없이 취소되었습니다.

Matthew Etheridge, administrateur de Streamline Health Solutions, a déclaré des cessions liées à une fusion entrée en vigueur le 08/12/2025. En vertu de l'accord de fusion daté du 29 mai 2025, la société est devenue une filiale entièrement détenue par Mist Holding Co., et chaque action ordinaire en circulation de Streamline a été annulée et convertie en droit de recevoir $5.34 en espèces par action. Le dépôt précise que les chiffres ont été ajustés pour tenir compte d'un fractionnement inversé d'actions 1-for-15 effectué le 4 octobre 2024.

Le Formulaire 4 indique que M. Etheridge a cédé 30,876 actions ordinaires, se retrouvant avec 0 action ordinaire détenue à titre bénéficiaire après la transaction. Il signale également que 61,403 actions sous-jacentes issues de warrants de la société (prix d'exercice indiqué $5.85) ont été annulées ; les warrants dont le prix d'exercice est égal ou supérieur à la contrepartie de la fusion ont été annulés sans contrepartie.

Matthew Etheridge, Direktor von Streamline Health Solutions, meldete Veräußerungen im Zusammenhang mit einer Fusion, die am 08/12/2025 wirksam wurde. Gemäß dem am 29. Mai 2025 abgeschlossenen Fusionsvertrag wurde das Unternehmen eine hundertprozentige Tochtergesellschaft von Mist Holding Co., und jede ausstehende Streamline-Stammaktie wurde annulliert und in das Recht umgewandelt, pro Aktie $5.34 in bar zu erhalten. Die Einreichung weist darauf hin, dass die Zahlen an einen 1-for-15 Reverse Stock Split angepasst wurden, der am 4. Oktober 2024 durchgeführt wurde.

Das Form 4 zeigt, dass Herr Etheridge 30,876 Stammaktien veräußerte und nach der Transaktion 0 Stammaktien vorteilhaft besitzt. Es berichtet außerdem über 61,403 zugrunde liegende Aktien aus Unternehmens-Warrants (Ausübungspreis angegeben mit $5.85), die annulliert wurden; Warrants mit Ausübungspreisen, die gleich oder höher als die Fusionsgegenleistung waren, wurden ohne Gegenleistung annulliert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Etheridge Matthew

(Last) (First) (Middle)
2400 OLD MILTON PARKWAY
BOX 1353

(Street)
ALPHARETTA GA 30009

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STREAMLINE HEALTH SOLUTIONS INC. [ STRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value 08/12/2025 D(1) 30,876 D (1) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy) $5.85(2) 08/12/2025 D(1) 61,403 (3) (3) Common Stock, $0.01 par value 61,403 (3) 0 D
Explanation of Responses:
1. This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2025, by and among the Issuer, Mist Holding Co. ("Parent"), and MD BE Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, effective as of August 12, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.01 per share, of the Company ("Common Stock") issued and outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive $5.34 in cash, without interest (the "Merger Consideration").
2. The Issuer effected a 1-for-15 reverse stock split of its common stock on October 4, 2024. The number of securities reported on this Form 4 has been adjusted to reflect the reverse stock split.
3. Pursuant to the terms of the Merger Agreement, at the Effective Time, each warrant to purchase shares of Common Stock (each, a "Company Warrant") that was outstanding and unexercised and had a per share exercise price that was less than the Merger Consideration was canceled and converted into the right to receive (i) a cash payment equal to (A) the number of shares of Common Stock subject to the Company Warrant immediately prior to the Effective Time multiplied by (B) the excess, if any, of (x) the Merger Consideration over (y) the exercise price per share of Common Stock of such Company Warrant, less applicable withholding taxes. Each Company Warrant that was outstanding and unexercised with a per share exercise price that was equal to or greater than the Merger Consideration was canceled for no consideration.
/s/ Matthew Etheridge 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for STRM report on 08/12/2025?

The Form 4 reports that common shares were converted into the right to receive $5.34 per share under the Merger Agreement effective 08/12/2025, and certain warrants were canceled.

How many Streamline common shares did Matthew Etheridge dispose of?

The filing reports disposition of 30,876 common shares, with 0 common shares beneficially owned following the transaction.

What happened to Streamline warrants held by the reporting person?

The Form 4 shows warrants covering 61,403 underlying shares; warrants with an exercise price of $5.85 were canceled per the Merger Agreement, and the reporting person holds 0 thereafter.

Was there a stock split adjustment noted in the filing?

Yes. The issuer effected a 1-for-15 reverse stock split on October 4, 2024, and the numbers on the Form 4 were adjusted accordingly.

What agreement governed the conversions and cancellations described in the Form 4?

The transactions were governed by the Agreement and Plan of Merger dated May 29, 2025, among the issuer, Mist Holding Co., and MD BE Merger Sub, Inc.
Streamline Health Solutions In

NASDAQ:STRM

STRM Rankings

STRM Latest News

STRM Latest SEC Filings

STRM Stock Data

23.23M
3.60M
17.45%
26.05%
0.51%
Health Information Services
Services-computer Integrated Systems Design
Link
United States
ALPHARETTA